Tumor
Conditions
Interventions
Group A:docetaxel
Group B:docetaxel+rocaltrol
Sponsors
The First Affiliated Hospital, Jinan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years when signing the Informed Consent Form (ICD); 2. According to WHO standards, advanced NSCLC has been diagnosed in the past for at least 6 months; 3. Resistance or relapse; 4. 25 OH Vitamin D<30 ng/mL; 5. Willing and able to comply with the research process of the program; 6. Be able to understand and sign the study informed consent, if it is illiterate, willing to make a handprinting on the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Those with organ failure; Heart: Grade III and Grade IV; Liver: Reach Grade C of Child-Turcotte liver function classification; Kidney: renal failure and uremia stage; Lung: severe symptoms of respiratory failure; Brain: people with impaired consciousness. 3. Patients with a history of organ transplantation; 4. People with uncontrollable infectious diseases or other serious diseases, such as HIV positive; 5. Patients with systemic autoimmune diseases or immunodeficiency diseases; 6. Patients with allergies; 7. T cell tumors, such as T cell lymphoma, etc.; 8. Chronic diseases that require immune preparations or hormone therapy; 9. Participated in other clinical trials in the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response; | — |
Countries
China
Contacts
Public ContactXinhai Zhu
The First Affiliated Hospital, Jinan University
Outcome results
None listed